Cat. #151873
Anti-SPRED1 [M23-P2G3]
Cat. #: 151873
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Sprouty-Related, EVH1 Domain Containing 1 (SPRED1)
Class: Monoclonal
Application: ELISA ; IF ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Ayham Alnabulsi
Institute: Vertebrate Antibodies Limited
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-SPRED1 [M23-P2G3]
- Clone: M23P2G3
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: ELISA ; IF ; WB
- Description: Sprouty-Related, EVH1 Domain Containing 1 (SPRED1) is a member of the Sprouty family of proteins and is phosphorylated by tyrosine kinase in response to several growth factors. SPRED1 can act as a homodimer or as a heterodimer with SPRED2 to regulate activation of the MAP kinase cascade. Defects in SPRED1 can cause neurofibromatosis type 1-like syndrome (NFLS) and contribute to Legius syndrome and childhood leukemia.
- Immunogen: Peptide Sequence YVPLRMCHR (amino acids 420 428)
- Isotype: IgG1 kappa
- Myeloma used: P3X63Ag8.653
- Recommended controls: ELISA- Peptide immunogenWestern Blot- Hela whole cell extractImmunofluorescence- Hela Cells
Target Details
- Target: Sprouty-Related, EVH1 Domain Containing 1 (SPRED1)
- Tissue cell line specificity: ELISA- Peptide immunogenWestern Blot- Hela whole cell extractImmunofluorescence- Hela Cells
- Target background: Sprouty-Related, EVH1 Domain Containing 1 (SPRED1) is a member of the Sprouty family of proteins and is phosphorylated by tyrosine kinase in response to several growth factors. SPRED1 can act as a homodimer or as a heterodimer with SPRED2 to regulate activation of the MAP kinase cascade. Defects in SPRED1 can cause neurofibromatosis type 1-like syndrome (NFLS) and contribute to Legius syndrome and childhood leukemia.
Applications
- Application: ELISA ; IF ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -20° C
- Shipping conditions: Shipping at 4° C
